Celldex shares dinged after it redesigns PhIII cancer study; GenVec gains $3M milestone; AcelRx CEO preps an exit;

@FierceBiotech: Merck partners with Bind on a pair of new cancer drug programs. News | Follow @FierceBiotech

@JohnCFierce: Aeterna Zentaris bottoms out after a stinging FDA rejection--$AEZS down 51%. More | Follow @JohnCFierce

@DamianFierce: So $ABBV's not disclosing a PDUFA date for its HCV combo, but its June priority review disclosure puts in mid Dec. June release | Follow @DamianFierce

@EmilyMFierce: Glaxo hep C vaccine delivers promising early results. FierceVaccines story | Follow @EmilyMFierce

> Celldex Therapeutics reported that a slower-than-expected rate of patient recruitment forced it to change the Phase III design for glembatumumab (CDX-011), in development for triple negative breast cancer. The biotech's shares fell Wednesday evening before bounding back on Thursday. Story

> GenVec says it has picked up a $3 million milestone from Novartis. Release

> Redwood City, CA-based AcelRx says its CEO, Richard King, is leaving the company. He will stay on until a successor is found. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Medtronic in high spirits over positive study results for drug-coated balloon. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Government report says device tax will not deter innovation. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Medtronic in high spirits over positive study results for drug-coated balloon. More | Follow @EmilyWFierce

> Dexcom snags FDA approval for next-gen artificial pancreas tech for blood glucose monitoring system. Report

> Stryker agrees to pay $1.43B to settle recalled hip implant lawsuits. Story

> Dozens of lawsuits filed in growing counterfeit spinal screw implant scandal. Article

Pharma News

@FiercePharma: Top-read in FiercePharmaMarketing Weds: Sanofi revamps 'underperforming' U.S. sales team under new diabetes chief. Article | Follow @FiercePharma

@EricPFierce: Boehringer Ingelheim unloads US API plant to Chinese company even as it expands in China. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's FiercePharmaMarketing newsletter. Subscribe to get it weekly. | Follow @CarlyHFierce

> FDA yanks Ranbaxy's tentative approval for generic Nexium. Item

> Nexium reprieve lets AstraZeneca spend, spend, spend to prep for 2015 knockdown. Article

> Perrigo snaps up OTC specialist Omega in deal worth $5.7B. News

Pharma Manufacturing News

> Two more guilty pleas in spectacular burglary of Lilly warehouse. News

> Valeant labeling snafu affects Sanofi's Aplenzin, as well as Valeant's vaseretic. Report

> Ranbaxy manufacturing mess costs it exclusive for Valcyte generic. More

> Baxter spends $10M expanding admixing facility in Canada. Story

> German meat company invests $30M in plant for traceable heparin ingredients. Article

Vaccines News

> Inhaled Ebola vaccine may provide higher protection rate. News

> Sanofi, armed with more strong PhIII dengue data, sets sights on 2015 rollout. Report

> Glaxo hep C vaccine delivers promising early results. Story

> Sanofi, Protein Sciences win flu jab nods in older adults. Item

> PATH Malaria Vaccines Initiative nets $156M from Gates Foundation. Article

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.